Research-based content. This article is based on published research and publicly available pricing data. It is not medical advice. Do not start, stop, or change any medication without consulting a licensed healthcare professional. See sources below.
Insulin Glargine (Lantus) in India — Biosimilar Price Comparison & Manufacturers
Approximate Price Comparison (per month supply)
India
$12 – $25
US
$300 – $450
UK
$80 – $130
Prices are approximate and vary by dosage, brand, and pharmacy. Based on publicly available data.
Indian Manufacturers
In April 2026, the FDA approved yet another interchangeable biosimilar to Lantus — Langlara (insulin glargine-aldy). This approval continues to erode the monopoly pricing that kept insulin unaffordable for millions. But India solved this problem years ago.
Indian-manufactured insulin glargine costs $12–$25 per month. The same molecule in the US costs $300–$450. Here is the complete picture for international patients considering India for diabetes care.
India’s Insulin Manufacturing Dominance
India is home to 101 million people with diabetes — the world’s second-largest diabetic population. This massive domestic demand drove Indian pharmaceutical companies to build world-class insulin manufacturing infrastructure decades ago.
Biocon is the standout story. The Bengaluru-based company:
- Produces insulin for 4 million patients globally
- Operates one of the world’s largest insulin manufacturing facilities
- Achieved the first-ever US FDA interchangeable biosimilar insulin designation (Semglee)
- Exports to 100+ countries including the US, EU, Japan, and Australia
| Indian Manufacturer | Product | FDA Status | Annual Capacity |
|---|---|---|---|
| Biocon | Semglee (glargine biosimilar) | FDA Interchangeable | 1 billion+ units |
| Wockhardt | Glaritus (glargine) | WHO Prequalified | Large scale |
| Intas | Basalog (glargine) | DCGI Approved | National scale |
| Lupin | Insulin glargine | In development | — |
The 2026 FDA Biosimilar Landscape
The FDA’s April 29, 2026 approval of Langlara reinforces the shift toward biosimilar insulin in the US market. But even with biosimilars, US prices remain 10–15x higher than Indian prices for the identical molecule:
| Product | US Monthly Cost | India Monthly Cost |
|---|---|---|
| Lantus (Sanofi original) | $400 – $500 | Not sold |
| Semglee (Biocon biosimilar) | $150 – $200 | $12 – $20 |
| Langlara (new biosimilar) | $120 – $180 (estimated) | Not yet launched |
| Indian market glargine | — | $12 – $25 |
The price gap persists because US biosimilar pricing is controlled by pharmacy benefit managers (PBMs) who capture most savings through rebates rather than passing them to patients.
Once-Weekly Insulin: The Next Revolution
Awiqli (insulin icodec) was approved March 26, 2026 — replacing 365 daily injections with 52 weekly injections per year. For Type 2 diabetics, this is the most significant convenience improvement since insulin pens replaced syringes.
Awiqli is currently available only in the US at premium pricing. Indian biosimilar development is expected but will take years. In the meantime, Indian daily insulin glargine remains the most cost-effective long-acting insulin option globally.
What Medical Tourists Should Know
Hospital-Based Diabetes Programs in India
Major Indian hospitals offer comprehensive diabetes management packages for international patients:
- Endocrinology consultation and metabolic workup: $50–$150
- Continuous glucose monitoring setup: $30–$80
- 3-month insulin supply: $36–$75 (vs $900–$1,350 in US)
- Complete diabetes checkup package: $200–$500
These packages at hospitals like Manipal Hospitals, Apollo, and Narayana Health include specialist consultations, lab work, dietary counseling, and medication at Indian market prices.
Carrying Insulin Home
Practical considerations for traveling with insulin from India:
- Storage: Unopened insulin pens must stay at 2–8°C. Use an insulated travel case with gel packs for flights.
- Prescription: Carry the original prescription from your Indian doctor plus a medical necessity letter
- Quantity: Most countries allow 90-day personal supply. Declare at customs if required.
- Airlines: Insulin and syringes/pens are allowed in carry-on luggage with medical documentation
Cost Comparison: Annual Insulin Spend
| Scenario | Annual Cost |
|---|---|
| Lantus in US (uninsured) | $4,800 – $6,000 |
| US biosimilar (Semglee) | $1,800 – $2,400 |
| Indian insulin glargine | $144 – $300 |
| India trip + 1 year supply | $800 – $1,500 (including travel) |
For uninsured US patients, a round-trip flight to India plus a year’s supply of insulin costs less than 3 months of Lantus at US retail prices.
India’s Regulatory Framework for Insulin
India’s insulin market is regulated at multiple levels:
- CDSCO (Central Drugs Standard Control Organisation) approves all insulin products
- NPPA caps prices on essential medicines including insulin
- WHO-GMP compliance is mandatory for export-oriented manufacturers
- Jan Aushadhi stores (government pharmacies) sell insulin at further reduced prices
The combination of price regulation, manufacturing scale, and competitive market dynamics keeps Indian insulin prices among the lowest in the world while maintaining quality standards acceptable to the US FDA, WHO, and European regulators.
Sources & References
- FDA Approval — Langlara (insulin glargine-aldy), Interchangeable Biosimilar to Lantus, April 29, 2026
- Biocon Biologics — Semglee (insulin glargine-yfgn) Prescribing Information
- WHO Essential Medicines List, 2023 — Insulin Glargine listing
- NPPA Price Control Order — Insulin pricing schedules, India
- American Diabetes Association — Standards of Care, 2026
- IDF Diabetes Atlas, 10th Edition — India statistics
Frequently Asked Questions
How much does insulin glargine cost in India vs the US?
Insulin glargine (Lantus equivalent) costs approximately $12–$25 per month in India compared to $300–$450 per month in the US. This 90-95% price difference exists because Indian manufacturers like Biocon produce FDA-quality biosimilars at scale with lower manufacturing costs, and India's NPPA regulates insulin pricing.
Is Biocon's insulin glargine biosimilar FDA-approved?
Yes. Biocon's Semglee (insulin glargine-yfgn) was the first interchangeable biosimilar insulin approved by the US FDA. In April 2026, the FDA also approved Langlara (insulin glargine-aldy) as another interchangeable biosimilar to Lantus, further expanding biosimilar insulin options.
What is an interchangeable biosimilar insulin?
An interchangeable biosimilar can be substituted at the pharmacy for the reference product (Lantus) without the prescribing doctor's intervention — just like a generic drug. This designation requires additional clinical data proving the biosimilar produces the same clinical result in any given patient. Biocon's Semglee was the first insulin to receive this designation.
Can medical tourists bring insulin from India back home?
Most countries allow travelers to carry a personal supply of prescribed medication (typically 90 days). Insulin must be stored properly during transport (2-8 degrees Celsius for unopened pens). You need a valid prescription from a registered doctor and should carry a medical letter. Check your destination country's customs rules for specific quantities allowed.
Why is insulin so much cheaper in India?
Three reasons: India's price regulation body (NPPA) caps insulin prices under the DPCO. Indian manufacturers like Biocon have invested billions in biosimilar insulin production at massive scale. And India's cost of manufacturing is structurally lower — the same WHO-GMP compliant production costs 70-80% less than in the US or Europe.
What about the new once-weekly insulin (Awiqli) in India?
Awiqli (insulin icodec) was FDA-approved March 26, 2026 as the first once-weekly basal insulin. It is not yet available in India. Indian biosimilar manufacturers are expected to develop alternatives once the patent landscape allows, but this could take several years. Currently, daily insulin glargine remains the standard long-acting option available in India at significantly lower cost.
Disclaimer: This content is for informational and educational purposes only, based on published research and publicly available data. It does not constitute medical advice, diagnosis, or treatment recommendations. Drug prices are approximate and vary by dosage, formulation, brand, and pharmacy. Always consult a qualified healthcare professional before making any decisions about medication. Fittour India is not a pharmacy, drug seller, or licensed medical provider.